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ABSTRACT
Objective: Glioblastoma (GBM) is the most common adult primary brain tumour. Human
cytomegalovirus (HCMV) has been studied for the past decade and conflicting results have
been reported with no conclusive role has yet been established. Human papillomavirus (HPV)
is involved in the pathogenesis of many cancers and has high prevalence in cervical and oral
cancer patients of Pakistan. The objective of our study was to identify the prevalence of
HCMV and HPV in Pakistani primary GBM patients.
Methods: 112 primary GBM biopsies were analyzed. HCMV and HPV infection was
investigated using nested and conventional PCR respectively. Positive HPV samples were
further confirmed through sequencing. HPV status was correlated with histology and
expression of other frequently mutated GBM molecular markers.
Results: Our data had 68% males and 32% females. HCMV was detected in only 1 patient
while HPV infection was present in 28% of patients with no cases of HPV and HCMV coinfection. We report for the first time that a majority of HPV positive GBM patients
harboured types 16 and 18 both. Among them, 16% were HPV-type16 and 20% were HPVtype 18. HPV infected patients had longer survival times but this was not statistically
significant. Most commonly overexpressed molecular marker in HPV positive patients was
COX2, and no histological changes were seen in HPV positive GBM cases.
Conclusions: The presence of a single HCMV positive is intriguing. Additionally, we
discovered a substantially high 28% prevalence of HPV in GBM patients. The role of viruses
in the gliomagenesis warrants further investigation.
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INTRODUCTION
Glioblastoma multiforme (GBM), presenting as a common malignant primary brain tumour
(WHO grade IV astrocytoma), is the deadliest brain tumour with a poor prognosis and an
almost unavoidable tendency of relapse within a short period of time. The average patient
survival rate is 14.6 months even after a rigorous multimodal treatment consisting of surgery,
chemotherapy and radiotherapy. The 5-year survival rate with maximum available
multimodal therapy is a mere 5.5% 1,2.
GBM has an incidence of 3.2 per 100,000 adults in the US population 3. In Pakistan, it
formed the largest subtype of astrocytic tumours (40.4%), as was reported in a single-center
study of 761 cases of CNS tumours conducted in the years 2009-2013 4. The current available
treatment constitutes safe surgical resection, radiation therapy and medications including
temazolamide (TMZ) and as of latest, avastin, which may marginally improve quality of life
but not significantly prolong survival 2,5.
Several environmental and genetic factors have been investigated but none has been
identified as a risk factor for the larger proportion of GBMs. Cigarette smoking, alcohol use,
drug use of any kind or dietary intake of N-nitroso compounds and the use of mobile phones
have all been studied and revealed insubstantial evidence of any association with GBM 6.
However, there is growing evidence and consensus for the association of certain viruses with
GBM 7.
Human cytomegalovirus (HCMV) is a β-herpes virus infamous for developing encephalitis
in-utero and in immunocompromised adults. This double-stranded enveloped DNA virus is
complex in its virology with 59 viral proteins and 70 host proteins identified, with mostly
unknown functions 8. It persists as a latent life-long infection since it can control immune
responses effectively, and is asymptomatic at primary infection in healthy adults 9. Not
regarded as an oncogenic virus, HCMV is instead proposed to be an oncomodulator, meaning
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it infects tumour cells and increases their malignancy without direct transformation 10.
Moreover, it has also shown oncogenic transformation potential in cancers of the breast 11.
The first study to report HCMV in GBM was conducted by Cobbs et al. in 2002 12 and ever
since there have been many studies citing presence and others reporting absence of HCMV in
glioblastoma 7,13-18.
Along with HCMV, Human papillomavirus (HPV) is also being investigated for any
association with high grade gliomas. HPV has over 200 recognized types and belongs to the
Papillomaviridae family 19. It is an oncogenic virus notably associated with cervical
carcinoma as a causative agent and has increasingly become popular in vaginal, penile and
even oropharyngeal carcinoma 20-22. The type most commonly responsible for oncogenesis is
the high-risk type HPV16 and HPV18 while low-risk types like HPV6 are more often linked
with benign lesions 19,23. E6 and E7 are the core genes in HPV, driving the dysregulation of
cell proliferation and the apoptotic pathways 24-26. These genes have been shown to amplify
cell proliferation and self-renewal characteristics of neural progenitor cells presumably by
breaking down p53 and pRb proteins, giving rise to the effects HPV oncogenic proteins may
have on the CNS 27. So far, only two studies have investigated the presence of HPV in GBM
and revealed that a high percentage of GBMs are infected by HPV 18 and this in turn leads to
a worse prognosis 28.
The subject of HPV and HCMV co-infection has also garnered interest. HPV and HCMV coinfection has been reported to lead to a two-fold increase in lymph node metastasis in cervical
tumours 29. Additionally, HCMV infection was also associated with a six-fold increase in
integrated forms of HPV16 in cervical lesions and contributed to the development of cervical
cancer 30.
Apart from viruses, overexpression of certain molecular markers is also thought to contribute
to GBM development and progression. The expression of Epidermal Growth Factor Receptor
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(EGFR), Cycloxygenase-2 (COX2), Cyclin D1 and p53 have been found to be elevated in
GBM and have been correlated with clinical outcome and treatment response. The
pathogenesis of GBM is not clearly understood despite much research and a viral infection is
believed to be responsible for at least some GBM cases. The role of Human Cytomegalovirus
(HCMV) in GBM formation is most convincing among all viruses, but unanimous evidence
for its use as a therapeutic agent and possible oncogenic factor is missing. Since HPV has
high incidence in our population and is thought to play a part in various cancers, we aim to
study its presence in GBM patients as well and any HCMV/HPV co-infection that may be
present.
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MATERIALS AND METHODS
This study was a retrospective series. A total of 112 patients who had been diagnosed with
and treated for GBM at Aga Khan University Hospital (AKUH) in the years 2015-2016 were
recruited. The study was given ethical approval by the Ethical Review Committee of AKUH
(ERC number: 4197-Sur-ERC-17). Written informed consent for participation was taken
prior to the study and patient information and follow up data was collected using medical
records and patient follow up visits. Formalin-fixed paraffin-embedded biopsies were used to
extract genomic DNA by QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden Germany)
according to the manufacturer’s protocol. 25 μL PCR reaction mixtures for CMV, HPV and
β-globin were prepared using (GoTaq® Green Master Mix) according to manufacturer’s
protocol. All primers sequences used are outlined in Table 1.

CMV detection

Nested PCR was performed using external and internal oligonucleotide primers specific for
CMV glycoprotein B gene 31 and PC03/PC04 for β-globin. The PCR thermal profile started
with initial denaturation for 15 min at 95°C. Then 45 amplification cycles were performed as
follows: denaturing at 94°C for 30s, annealing for 30s at 56°C, and extension at 72°C for 40s.
A final extension at 72°C for 10 min completed the PCR amplification. For β-globin, the
PCR thermal profile was 94°C for 5 min, followed by 40 cycles of 94°C for 30s, 51°C for
30s, 72°C for 30s, and 5 min final extension at 72°C.

HPV detection

Samples were analyzed for HPV by PCR using four sets of primers, i.e., GP5/GP6, general
primers for HPV; TS16-A/TS16-B and TS18-A/TS-18B as subtype-specific primers for HPV
subtypes 16 and 18, respectively 32 and PC03/PC04 for β-globin 33. The PCR thermal profile

Ali. 7
was as follows: 95°C for 5 min, then 40 cycles of 94°C for 30s, 45°C for 30s, 72°C for 30s,
and final extension of 5 min at 72°C. PCR conditions for HPV 16 and 18 were the same as
those for general primers (GP), except that the annealing temperatures were 58°C and 60°C,
respectively. For β-globin, the thermal profile is mentioned above.

PCR products were separated on agarose gel (2%) premixed with 0.5 µg/ml ethidium
bromide. The size of the resolved products was determined either with 100bp Plus DNA
ladder. Agarose gel was run at 120 V for 15 minutes, observed under UV light and
photographed.

Samples that resulted positive for HPV were confirmed by sequencing. Amplified PCR
products of general and type-specific HPV16 and HPV18 were sent to Macrogen South
Korea, Inc. (http://www.macrogen.com/ko/main/index.php) for gene sequencing. The
sequenced data was then analysed using BLAST (Basic Local Alignment Search Tool)
available online at the website of National Centre for Biotechnology Information.

Molecular markers expression

Samples that resulted positive for HPV were further analyzed using immunohistochemistry
(IHC) for the status of EGFR, COX2, Cyclin D1 and p53. All staining was performed using
primary antibodies from Dako, Denmark, according to manufacturer’s recommendations,
previously optimized protocols and scoring criteria 34,35.

Statistical methods

Analysis was performed using SPSS version 22. Descriptive analysis were performed, for
continuous variables Mean± S.D or Median (IQR) was reported depending on the normality
assumption of the variables and assessed for the 2 groups (i.e. HPV positive and HPV
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negative) by independent t test or Wilcoxon rank sum (Mann Whitney test) respectively. For
Categorical variables frequency with percentages was reported and was assessed for the 2
groups by chi-square test of independence if frequency in each cell is ≥5 and if frequency
was less than 5 in any cell fisher’s exact test was used.

Follow-up time for each patient was calculated in months. The overall survival time was
measured from the date of surgery to the date of death (treatment failure) or, if the patient
was alive, then until the date of last follow-up. Patients who were alive at the time of last
contact were considered as censored observation in overall survival analysis. Kaplan-Meier
survival curves, log-rank tests and Cox proportional hazards regression analysis were used to
compare overall survival (death). A second proportional hazard regression model adjusted for
the other covariates of the study was used to examine the independent effect of treatment.
Adjusted Hazard Ratio (aHR) with their 95% CI was reported. A p-value of < 0.05 was
considered as significant.
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RESULTS
There were a total of 112 patients in our study comprising of 76 (68%) males and 36 (32%)
females. Patients ranged from 6 - 81 years of age with the mean age of our study population
being 47.83 years (SD ± 15.85). The type of brain tumour in all patients was a glioblastoma
(WHO astrocytoma Grade IV).
HCMV was positive in a single patient, who was a 61 year old female and tested negative for
HPV status. For HPV detection, general primers were used which resulted positive in 31
(28%) patients. Out of these 31 positive specimens, 18 (16%) were detected as HPV16
positive, 22 (20%) were HPV18 and 2 specimens were not type 16 or 18 and were classified
as HPV others (Figure 1). Co-infection of HPV16 and HPV18 was seen in 11 out of 31 cases.
For confirmation of HPV presence, positive PCR products for HPV general and type specific
16 and 18 were confirmed through sequencing. There was 99% compatibility between our
PCR and gene sequencing results. A total of 11 patients exhibited co-infection of HPV16 and
HPV18 both. Any correlations between HPV positivity and patient clinicopathological
factors were tested using Chi-square or Fishers’ exact test, wherever necessary. There was no
significant association between any patient factor and HPV status as listed in Table 2.
The status of molecular markers EGFR, COX2, Cyclin D1 and p53 was tested using IHC on
the HPV positive specimens (n=31). Each case of HPV positive GBM overexpressed at least
one of the molecular markers tested, with COX2 being the most frequent (n= 20/31),
followed by Cyclin D1 (n= 19/31), p53 (n= 15/31) and EGFR (n= 14/31). Co-expression of
EGFR, Cyclin D1 and COX2 all together was also regularly observed (16%), but none of the
molecular markers were correlated with one another, as established using the Phi test (p=
>0.05). Furthermore, H&E slides of all cases were reviewed by two independent
histopathologists to identify any differentiating features based on HPV infection. However,
no remarkable differences in microscopic features were observed. Typical microscopic
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features of GBM such as presence of necrotic areas, “chicken-wire” network of blood
vessels, pleomorphic cells with elongated hyperchromatic nuclei, eosinophilic cytoplasm and
endothelial proliferation were observed. All cases were positive for GFAP and an
overwhelming majority had increased ki-67 expression, though to varying degrees.
To study the effect of HPV infection on overall survival of glioblastoma patients, KaplanMeier survival curves, log-rank tests and Cox proportional hazards regression analysis were
performed. Complete survival data was available for 60 out of 112 patients. The overall mean
survival time for the study participants was 10.3 months, while the survival time of the
CMV+ patient was 16 months. Figure 2 shows the Kaplan-Meier curves for HPV+ and HPVpatients. It was observed that HPV positive patients had longer survival times (13 months) in
comparison to HPV negatives ones (9 months). However, this did not translate to statistical
significance (Table 3). Moreover, age was significantly correlated with overall survival as
with every one year increase in age the hazard of death was increased by 3%.
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DISCUSSION
This study is the first to explore the role of infectious agents HCMV and HPV in
glioblastoma patients of Pakistan. We found a high prevalence of HPV in our GBM
population and a single case of HCMV infection. A novel finding of our study was the coinfection of HPV16 and 18 found in 11 out of 31 cases. Upon correlation with overall
survival, it was found that HPV infection did not have any statistically valid effect on the
prognosis of GBM patients, although HPV positive patients did have longer survival times
than their negative counterparts. We further investigated any histological differences
occurring due to HPV infection, but found no discerning features in the HPV positive cases.
The expression of commonly used biomarkers EGFR, COX2, Cyclin D1 and p53 was
assessed in HPV positive cases and at least one marker was overexpressed in all cases, with
COX2 being the most common. The trio of EGFR, COX2 and Cyclin D1 was overexpressed
together in 16% cases, although no correlations among any of the markers could be
established statistically.
There are certain features typical to the majority of GBM cases. These include the male sex,
age close to 45 years, white race, prior exposure to ionizing radiation and certain underlying
genetic disorders such as tuberous sclerosis, neurofibromatosis type 1 & 2, Turcot syndrome
and Li-Fraumeni syndrome2. These findings are consistent with our cohort, as there were
76% males as compared to 36% females and the mean age was 47 years. Similar figures were
reported by Ahsan et al36. who performed a single-centre study showing that the mean age
was 47 years in Pakistan as compared to the 64 years on presentation in the US1.
Viral infections have been linked to the development of a spectrum of clinical disorders
including cancer. In the Pakistani population, the seroprevalence of HCMV was found to be
very high at 93.2% for IgG and 4.3% for IgM respectively37. Other local studies have found
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HCMV infection to be responsible for congenital defects among neonates and 6% of
Pakistani women of childbearing age are at risk of primary infection38,39.
Over a decade has passed since the discovery of HCMV in a few GBM samples by Cobbs et
al.12. In our cohort of 112 patients we found only one case of HCMV infection. There was no
correlation of HCMV positivity with any of the clinicopatholgical factors tested. Another
study by Lau et al. also reported complete absence of HCMV in various carcinomas and
sarcomas using immunohistochemistry, in situ hybridization and PCR13. Since the results of
Cobbs et al. have not been reproduced satisfactorily, the association of HCMV with GBM is
still not established. It is hypothesized that HCMV may give rise to gliomagenesis, enhance
tumourigenesis or reactivate itself in tumour formation and the latest consensus is that the
role of HCMV cannot be ignored7. The results of HCMV may not be sufficient to show a
direct association with GBM, however, the possibility of a link cannot be completely ruled
out for the population of Pakistan. As suggested by previous researches conducted in Japan
where HCMV was not detected, geographical variation may be a possible explanation for this
outcome18. Various studies have concurred that the presence and role of HCMV in GBM
cannot be excluded at the very least7.
The Pakistani population also suffers from high HPV incidence. A study by Bruni at al. in
2012 found that 88% of all cases of cervical carcinoma were due to HPV infection, while the
incidence of HPV-related other cancers in males was 2.4 per 100,000 40. Moreover, HPV16
was found to be significantly associated with cervical cancer in Pakistani women and oral
squamous cell carcinoma in Pakistani men41,42.
HPV, in its limited research with brain tumor tissue, has emerged as a virus consistent in its
outcomes with all three studies, including ours. Vidone et al. established the existence of
HPV in GBM specimens from the eastern European population where 23% of samples tested
positive, in which 25% showed HPV16 dominance associated with poor prognosis28. The
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first study done on the Asian population to check for the presence of eight known oncogenic
viruses showed 21% of samples to be HPV positive while no other viruses were detected18.
Our results show presence of HPV in 28% of GBM patients, out of which the majority were
infected with HPV18. We also found positivity of HPV16 and 18 both in 11 cases which was
a finding unique to our cohort. Existing literature on Pakistani patients shows us that HPV16
was more prevalent than type18 for oral and cervical cancer both41,42. Moreover, in our
current GBM study as well as in the previously published oral cancer study42, the majority of
HPV positive patients were male. This begs further investigation into how males are more
susceptible or more exposed to HPV infections in oral as well as brain cancers.
As mentioned earlier, the E6 and E7 core genes of HPV can cause the dysregulation of
various processes responsible for oncogenic transformation in the CNS27. Moreover, heparin
sulfate proteoglycans (HSPG) have been found to be the primary binding sites for HPV
virions which are an element of the cellular components of the brain, as also suggested by
Vidone et al. 28,43,44.
The overexpression of molecular markers observed in HPV positive cases corresponds with
present literature. EGFR is found overexpressed in 60% of primary glioblastomas45 , COX2
in 75% of glioblastoma46, Cyclin D1 in 31% of low grade and 62% of high grade gliomas47
and p53 in 42% of low-grade and 64% of high grade gliomas48 . However, we did not find
any literature regarding the association of HPV and EGFR, COX2, Cyclin D1 and p53 in
GBM. Nevertheless, we did find overexpression of at least one biomarker in all HPV positive
cases and COX2 overexpression was the most common at 65%.
Our findings make a strong case for further investigation into the role of viruses in
gliomagenesis and the molecular basis for this neoplasia. If HPV is a causative factor for
GBM then preventive measures may be applied as is the case with HPV-induced cervical
cancer patients which may prolong patient survival.
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CONCLUSIONS
Our findings make a strong case for further investigation into the role of viruses in
gliomagenesis and the molecular basis for this neoplasia. Since CMV was very scarce in our
study we propose other factors may be influencing the development of gliomas in the
Pakistani population. If HPV is a causative factor for GBM, which needs further
investigation, then preventive measures may be applied as is the case with HPV-induced
cervical cancer patients which may prolong patient survival.
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FIGURE CAPTIONS
Figure 1: Kaplan Meier survival curves in 60 GBM patients selected according to (A) CMV
status, (B) HPV status, (C) HPV16 status and (D) HPV18 status

Figure 2 (A): PCR amplification of HPV general, HPV type 16 and HPV type 18 in GBM
samples. Products were electrophoresed on 2% agarose gel and stained with ethidium
bromide. From left to right: sample 117 is HPV-, 118 and 119 are HPV+ with positive
control marked, DNA ladder of 100bp, positive control of HPV18, sample 4 HPV18+,
positive control of HPV16 and sample 4 HPV16+. It is to be noted that sample 4 has coinfection of HPV16 and HPV18
Figure 2 (B): PCR amplification of HCMV in GBM samples. Products were electrophoresed
on 2% agarose gel and stained with ethidium bromide. From left to right: DNA ladder of
100bp, negative control, positive control of CMV, samples 3, 5, 6 and 7 are CMV- and
sample 4 is CMV+.

TABLES

Table 1 Primers used for PCR
Primer

Sequence

HPV

GP5

TTTGTTACTGTGGTAGATACTAC

General

GP6

GAAAAATAAACTGTAAATCATATTC

HPV

TS16-A

GGTCGGTGGACCGGTCGATG

type16

TS16-B

GCAATGTAGGTGTATCTCCA

HPV

TS18-A

CCTTGGACGTAAATTTTTGG

type 18

TS18-B

CACGCACACGCTTGGCAGGT

β-globin

PC03

ACACAACTGTGTTCACTAGC

Target

Amplimer

gene

length

L1

155 bp

L1

96 bp

L1

115 bp

β-Globin

110 bp
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CMV

PC04

CAACTTCATCCACGTTCACC

CMVXF

TCCAACACCCACAGTACCCGT

glycoprotein
B

CMVXR CGGAAACGATGGTGTAGTTCG
CMVIF

TGACGGTCAAGGATCAGTGGC

CMVIF

GTAAACCACATCACCCGTGGA

146 bp

Table 2 Correlation of HPV status with patient characteristics (n=112)
HPV Status
Total

P value

Factors

Positive
(n=31)
N

Gender
Site of
Lesion

Living
Status
HCMV

%

N

Negative
(n=81)

%

N

%

Male
Female
Brain
Frontal

76
36
27
13

68
32
24
12

23
8
4
2

74
26
13
7

53
28
23
11

65
35
28
14

Parietal
Temporal
Occipital
FrontoParietal
Frontotemporal
Temporoparietal
ParietoOccipital
Others

16
28
2
8

14
25
2
7

7
8
1
3

23
26
3
10

9
20
1
5

11
25
1
6

3

3

0

0

3

4

7

6

2

7

5

6

4

4

3

4

3

4

4

4

3

10

1

1

Alive
Dead
LFUP
Positive
Negative

17
43
52
1
111

15
39
46
1
99

6
8
17
0
31

19
26
55
0
100

11
35
35
1
80

14
43
43
1
99

p-value considered significant at <0.05

267 bp

0.374
0.195

0.233

>0.99
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Table 3 Correlation of clinicopathologic factors with HPV status of GBM patients (n=60)
UNIVARIATE ANALYSIS
Overall survival
Factor
Age
Gender
Site of
Lesion

HPV
HPV16
HPV18

Factor

Age
HPV

Group
Male
Female
Brain
Frontal
Parietal
Temporal
Occipital
FrontoParietal
Frontotemporal
Temporoparietal
ParietoOccipital
Positive
Negative
Positive
Negative
Positive
Negative

Group

N

Months P-value

112
76
36
27
13
16
28
2
8

10
10
10
9
4
9
14
7

3

5

7
4

0.008*
.970
0.757

Hazard
ratios
1.029
0.987
1
0.885
0.837
1.838
1
0.395
1.050

95% Confidence
interval
Lower
Upper
1.008
1.052
0.498
1.957
0.396
0.315
0.587

1.979
2.220
5.753

0.051
0.236

3.031
4.681

1.753

0.225

13.692

15

0.277

0.036

2.125

12

0.450

0.058

3.463

31 13
0.399
0.715
81 9
1
18 13
0.537
0.744
94 10
1
22 13
0.498
0.753
90 10
1
MULTIVARIATE ANALYSIS
Overall survival
N
PHR
value

0.328

1.560

0.291

1.901

0.332

1.711

95% Confidence
interval
Lower
Upper
1.006
1.052
0.407
2.047

112
0.013* 1.029
Positive
31
0.825
0.913
Negative
81
*p-value considered significant at <0.05
Months for overall survival were calculated through Kalpan Meier Log Rank test
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